Oxcarbazepine Administration and the Serum Levels of Homocysteine, Vitamin B12 and Folate in Epileptic Patients: A Systematic Review and Meta-Analysis Publisher Pubmed



Rezaei S^{1, 2} ; Shabbidar S³ ; Abdulahi Abdurahman A³ ; Djafarian K⁴ Show Affiliations
Source: Seizure Published:2017

Abstract

The objectives were to determine the influence of oxcarbazepine (OXC) monotherapy on the serum levels of total homocysteine (tHcy), vitamin B12 and folate in patient with epilepsy pooling together case-control or interventional studies. A comprehensive literature search was done through four databases including MEDLINE/PubMed, Scopus, Embase and Web of Science from January 2000 to February 2016. A random effects model (the DerSimonian–Laird estimator) was utilized to pool the effect sizes of the individual studies. The between-study variance was assessed using the Q2 test (significance level p < 0.1) and quantified using the I2 test (>50% indicated evidence of heterogeneity). Overall, six studies found eligible for inclusion. The meta-analysis for tHcy revealed that the serum level of tHcy was no significant difference between patient on OXC monotherapy and healthy people [mean difference (MD) 0.31; 95% CI −1.05, 1.67, p = 0.653]. The meta-analysis for vitamin B12 [MD −46.51; 95% CI −113.63, 20.62, p = 0.174] and folate [MD −0.48; 95% CI −1.06, 0.11, p = 0.113] indicated that there was no significant difference between patients on OXC monotherapy and healthy people. In conclusion, the meta-analysis does not support the hypotheses that OXC monotherapy changes the serum levels of tHcy, vitamin B12 and folate. © 2016 British Epilepsy Association